Patents

Vesigen Therapeutics, a biotechnology company pioneering a novel extracellular vesicle delivery technology to develop transformative therapeutics, today...

The present invention relates to a pharmaceutical composition for prevention or treatment of non-alcoholic steatohepatitis, the composition comprising, as an active ingredient, exosomes isolated from induced...

Evox Therapeutics, a leading exosome therapeutics company, is pleased to announce that the Company has been granted another key patent by the European Patent Office (EPO). This new grant...

Ymir Genomics LLC (Ymir) and the Oregon Health & Science University (OHSU) Knight Cancer Institute today announced a licensing agreement and filed patent application that seeks to protect and promote newly-discovered high value urinary biomarkers for detecting cirrhosis and/or hepatocellular ...

Evox Therapeutics, a leading exosome therapeutics company, is pleased to announce that the Company has been granted a key patent by the United States Patent and Trademark Office (USPTO). This newly issued patent adds to the expanding foundational patent estate ...

ILIAS Biologics, a global leader in exosome-based therapeutics, announced today that the Company has been granted a key exosome engineering patent by the United States Patent and Trademark Office (USPTO).A patent for ILIAS's exosome engineering was...

Publication Number WO/2020/133912 Publication Date 02.07.2020 International Application No. PCT/CN2019/089478 International Filing Date 31.05.2019 Provided in the present invention is a method for simultaneously detecting exosome...

The inventions described herein are directed to bispecific antibodies that are capable of selectively targeting exosomes by specifically binding a first exosome-associated protein and Programmed Death Ligand-1 ("PD-L1") as a second exosome-associated protein. These bispecific antibodies can disrupt the suppression of anti-tumor activity by immune cells by...

Aethlon Medical, Inc, a therapeutic medical device and technology company focused on unmet needs in global health, announced today that it has received..

Fluxion Biosciences announced today a foundational patent has been issued for its ERASE-Seq technology, US patent 10,294,518, ‘Methods and Systems for Ultra-sensitive Detection of Genomic Alterations’. The ERASE-Seq technology and testing approach leverage inter-sample statistical analysis, rather than tracking of ...